Lisa Ricciardi, president and CEO of Cognition Therapeutics was recently a guest on Benzinga's All-Access. Cognition ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS. Regulators are due to ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) ...

Dementia affected an estimated 55.2million ... While that world does not currently exist, Dr Gourlay said the new drug is close to proving it can deliver just that. While a drug for Alzheimer's ...

A new pill that ‘slows down Alzheimer's ' is being considered for use in the NHS. Developed by a small British firm in ...

MEDICATIONS taken by thousands of Brits for to treat an overactive bladder have been linked to dementia in a new study. Some forms of the medication have been found to raise the risk of dementia ...

Eisai has a long history of developing drug therapies for dementia, starting with the cholinesterase ... In 2019, the Japanese government launched a new national strategy to try to prepare for ...

This is “equally important” as any new drug, Prof Hardy stresses ... the NHS the opportunity to kick a necessary improvement in dementia care down the road.” He is deeply concerned by ...